About a quarter of the dollars spent on healthcare in the United States may be wasted, a new analysis suggests.

Leeds, UK-based 4D Pharma and Merck/MSD are developing Live Biotherapeutics vaccines, a new class of medicines.

GlaxoSmithKline Plc is recalling the company’s heartburn medicine Zantac as a “precautionary measure” due to a probable cancer-causing impurity in the drug, Britain’s medicines watchdog said.

India’s ability to produce affordable generic drugs has led to the country’s reputation of being the “pharmacy of the world,” according to Dr. Reddy’s Vice President Radha Iyer.

The U.S. Supreme Court declined to hear Acorda Therapeutics Inc.’s appeal of a lower court ruling that allowed generic versions of the company’s multiple sclerosis treatment Ampyra.

Less than a month after the company’s Phase III brain cancer treatment failed, San Diego-based Tocagen is undergoing a restructuring and will reduce the employee workforce by 65 percent.

A British court ruled in favor of Vectura Group and the company’s partner Sandoz over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

A federal judge tossed out whistleblower lawsuits alleging that pharmaceutical giants Eli Lilly and Bayer used nurses to illegally boost sales of various prescription drugs in a kickback scheme.

Adicet Bio Inc., a biopharmaceutical company focused on the development of cancer therapies using gamma delta T cells, raised $80 million in private funding.

After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.